Nurix Therapeutics Inc. (NASDAQ: NRIX) announced updated clinical data from its ongoing Phase 1a/b trial evaluating bexobrutideg, an investigational BTK ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE